REG101
Cardiac regeneration post-myocardial infarction; Prevention/treatment of heart failure
Pre-clinicalActive
Key Facts
Indication
Cardiac regeneration post-myocardial infarction; Prevention/treatment of heart failure
Phase
Pre-clinical
Status
Active
Company
About Regencor
Regencor is a Stanford University spin-out developing a novel biologic therapy for cardiac regeneration post-myocardial infarction. Its lead asset, REG101, is a proprietary recombinant protein shown in animal studies to promote new cardiac muscle growth, reduce scar tissue, and restore function via subcutaneous delivery. The company is currently in IND-enabling studies, targeting human clinical trials in late 2025, and aims to address the significant unmet need in both acute MI and chronic heart failure markets. Leadership includes seasoned biotech executives and the scientific founder who discovered REG101's regenerative properties.
View full company profile